Giving patients more control over their condition

Chronic Granulomatous Disease (CGD) and severe, malignant osteoporosis (SMO)

Chronic Granulomatous Disease (CGD) and severe, malignant osteopetrosis (SMO) are rare, inheritable conditions that make disease management quite challenging. Approximately 1 in 200,000 live births in the US are diagnosed with CGD and 1 in 250,000 have SMO. Due to the rarity of both conditions, clinical diagnosis is often not initially made and manageable symptoms may change into life-threatening complications.

ACTIMMUNE® (Interferon gamma-1b) gives patients more control over their condition by reducing the number of serious infections associated with CGD and delaying the time to the progression of SMO.

Disease management, awareness, and patient education

Creating a disease management and awareness campaign for a drug that helps manage two rare conditions required the unique combination of client insight and creative muscle. The GA and Vidara partnership therefore led to the creation of a variety of marketing tactics that now span the realms of both print and digital communications.

The ACTIMMUNE® iPad Sales Aid, Actimmune.com, Information About CGD and ACTIMMUNE® Brochure, and the ACTIMMUNE® Journal Ad are just a few examples of tactics that helped make learning about the disease easy for Vidara representatives, physicians, and caregivers, so patients could receive the appropriate therapy at the right time.

ACTIMMUNE® is a registered trademark of Vidara Therapeutics, Inc. Purchased from InterMune in June 2012.